The COVID-19 pandemic accelerated a rising trend in the number of people seeking basic health care services outside of traditional clinical settings. Out of necessity to reduce strain on health care organizations caring for severely ill patients and to mitigate…
Enabling access to telehealth during the Covid-19 pandemic. This brief highlights Kaiser Permanente’s telehealth experience during the COVID-19 pandemic, and our long-standing commitment to high-quality, equitable access to telehealth. Download the brief. To learn more about the future of telehealth…
The following was authored by David Grossman, MD, MPH, Interim Senior Vice President, Social and Community Health, February 1, 2022 Early in my career, I worked on the Navajo Nation as a pediatrician for the Indian Health Service, the federal…
By Priti Krishtel, JD, Co-Founder, Co-Executive Director, I-MAK On December 7, 2020, the Kaiser Permanente Institute for Health Policy hosted the first of a 2-part virtual forum examining racial equity in the drug development system, including during initial investments and…
As drug prices continue rising unsustainably in the United States, patients and payers need to understand — and policy makers need to address — how pharmaceutical companies use patents to maintain monopolies and pricing power. Patents serve as important catalysts…
Biologics — drugs derived from living organisms that are used to treat conditions such as rheumatoid arthritis, multiple sclerosis, and some cancers — are the fastest growing component of prescription drug spending. While some of these drugs have fostered significant…
The term “pay-for-delay” refers to a tactic used by brand name drug manufacturers to delay a potential competitor from bringing a generic drug alternative to market. Usually in the form of a cash payment, pay-for-delay transactions result from a patent…
